Public disclosures

QCLS insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
PharmaCyte Biotech, Inc.

10% owner · Q/C TECHNOLOGIES, INC.

QCLS

Q/C TECHNOLOGIES, INC.

Other transaction
Filing details

SEC transaction code J

Series H Convertible Preferred Stock · Derivative security · Direct ownership · Reported balance after transaction: 3000 · Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment. · On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d)

2026-11-182026-11-20

3,000 shares/units

SEC 4Follow
PharmaCyte Biotech, Inc.

10% owner · Q/C TECHNOLOGIES, INC.

QCLS

Q/C TECHNOLOGIES, INC.

Exercise or conversion
Filing details

SEC transaction code X

Series G Long-Term Warrants · Derivative security · Direct ownership · Reported balance after transaction: 13318344 · Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment. · On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement.

2026-11-182026-11-20

851,304 shares/units

SEC 4Follow
PharmaCyte Biotech, Inc.

10% owner · Q/C TECHNOLOGIES, INC.

QCLS

Q/C TECHNOLOGIES, INC.

Exercise or conversion
Filing details

SEC transaction code X

Common stock · Direct ownership · Reported balance after transaction: 5152000 · On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement. · Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder.

2026-11-182026-11-20

4,982,272 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement